River Edge, NJ - Nephros, Inc., a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, announced today that the Renal Research Institute (“RRI”) is conducting an evaluation of the company’s hemodiafiltration (“HDF”) system. The Nephros HDF system is comprised of Nephros’ patented OLpur MD220 Mid-Dilution Hemodiafilter and OLpur H2H Hemodiafiltration Module. The module is designed for use with a standard hemodialysis machine to enable hemodiafiltration treatment of patients with chronic renal failure.
“RRI is a recognized leader in evaluating new technologies for dialysis practice,” stated Dr. Paul Mieyal, acting CEO of Nephros. “We are gaining valuable insights and feedback from RRI’s ongoing product evaluation as Nephros continues to explore all opportunities to make this important therapy broadly available to patients in this country. Evaluations by sophisticated partners such as RRI are helping us to define our best path forward.” Paul M. Zabetakis, MD, President of RRI, noted that “since its inception in 1997, RRI has served as a platform for research on innovative technologies and novel clinical approaches aimed at improving the lives of patients on dialysis. We look forward to participating in a thorough evaluation of hemodiafiltration and the Nephros HDF system.”
About Chronic Kidney Disease
Twenty-six million American adults have Chronic Kidney Disease (“CKD”) and millions of others are at increased risk. CKD is a progressive disease which ultimately leads to kidney failure. There are more than half a million patients whose kidneys have failed, requiring them to seek treatment. Of these patients, approximately 370,000 are receiving hemodialysis and this number is growing year on year. In 2011, the total medical care costs for Chronic Renal Failure reached an estimated $49.2 billion. On-line HDF represents an alternative treatment option for chronic renal failure with potential advantages over standard hemodialysis. On-line HDF is practiced in certain countries outside the U.S.; however, the Nephros HDF system is the only FDA cleared device currently available in the U.S.
About RRI
Renal Research Institute (RRI) was established in 1997 as a research division of Fresenius Medical Care AG & Co. KGaA. It is an administratively distinct institution which collaborates with a select group of US based dialysis facilities with strong ties to academic research centers. RRI trains research fellows from countries around the world in kidney disease-related clinical research. Its research spans a full spectrum of interests from molecular biology, clinical research, and pharmaceutical trials to epidemiology. The network of international collaborators has made it a global research institution with ties to Europe, Asia, Central and South America and Africa. RRI's primary goal is to produce measurable improvements in patient outcomes by building on a solid foundation of clinical research in nephrology. RRI evaluates the development and application of new technology to enhance the quality of patient care.
About Chronic Kidney Disease
Twenty-six million American adults have Chronic Kidney Disease (“CKD”) and millions of others are at increased risk. CKD is a progressive disease which ultimately leads to kidney failure. There are more than half a million patients whose kidneys have failed, requiring them to seek treatment. Of these patients, approximately 370,000 are receiving hemodialysis and this number is growing year on year. In 2011, the total medical care costs for Chronic Renal Failure reached an estimated $49.2 billion. On-line HDF represents an alternative treatment option for chronic renal failure with potential advantages over standard hemodialysis. On-line HDF is practiced in certain countries outside the U.S.; however, the Nephros HDF system is the only FDA cleared device currently available in the U.S.
About RRI
Renal Research Institute (RRI) was established in 1997 as a research division of Fresenius Medical Care AG & Co. KGaA. It is an administratively distinct institution which collaborates with a select group of US based dialysis facilities with strong ties to academic research centers. RRI trains research fellows from countries around the world in kidney disease-related clinical research. Its research spans a full spectrum of interests from molecular biology, clinical research, and pharmaceutical trials to epidemiology. The network of international collaborators has made it a global research institution with ties to Europe, Asia, Central and South America and Africa. RRI's primary goal is to produce measurable improvements in patient outcomes by building on a solid foundation of clinical research in nephrology. RRI evaluates the development and application of new technology to enhance the quality of patient care.
